Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta

• Published in: Bone (New York, N.Y.) N.Y.), 2003-03, Vol.32 (3), p.268-274
• Main Authors: Evans, K.D, Lau, S.T, Oberbauer, A.M, Martin, R.B
• Format: Article
• Language: English
• Subjects: Alendronate; Alendronate - pharmacology; Animals; Biological and medical sciences; Bisphosphonate; Bone Development - drug effects; Bones, joints and connective tissue. Antiinflammatory agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Genotype; Growth plate; Growth Plate - drug effects; Growth Plate - pathology; Humerus - drug effects; Humerus - growth & development; Humerus - pathology; Male; Medical sciences; Mice; Mice, Mutant Strains; oim; Osteogenesis imperfecta; Osteogenesis Imperfecta - drug therapy; Osteogenesis Imperfecta - pathology; Pharmacology. Drug treatments; Ulna - drug effects; Ulna - growth & development; Ulna - pathology
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/S8756-3282(02)00974-2

Alendronate, a bisphosphonate drug, has shown promise in reducing remodeling and bone loss in postmenopausal osteoporosis. Alendronate acts directly on the osteoclast, inhibiting its resorption capability. This inhibition of osteoclast activity has led to the use of bisphosphonates in the treatment of the osteogenesis imperfecta condition. Treatment of osteogenesis imperfecta with bisphosphonates enhances bone strength, but the consequences on linear bone growth are not well defined. Using the oim mouse model for type III osteogenesis imperfecta, two doses of alendronate, low (0.125 mg/kg/wk) and high (2.5 mg/kg/wk) were administered weekly via intraperitoneal injection starting at 4 weeks of age and ending at 12 weeks of age to assess the effects of alendronate on humerus and ulna length. The higher dose of alendronate reduced humerus and ulna length in the oim/wt and wt/wt genotypes for both sexes ( P < 0.05). The oim/oim humerus and ulna were not significantly affected by the higher dose of alendronate in females, but reduced bone length in males ( P < 0.0085). Proximal humerus growth plate area was affected by both genotype and alendronate dose and growth plate diameter was increased at the chondro-osseous junction by both alendronate doses ( P < 0.011). Genotype and alendronate dose affected growth plate height. The oim/oim genotype displayed taller growth plates. The high dosage of alendronate increased overall growth plate height, particularly within the hypertrophic zone, which suggests a failure of vascular invasion-induced apoptosis in the hypertrophic cells. In conclusion, these results indicate that high doses of alendronate (>2.5 mg/kg/wk) inhibit long bone length in mice through alteration of the growth plate and possibly reduced resorption at the chondro-osseous junction.